FORM 4

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

(Print or Type Responses)

1. Name and Address of Reporting Person*	2. Issuer Name **and** Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Dilmore Jillian	Baudax Bio, Inc. [BXRX]	____ Director ____ 10% Owner
(Last) (First) (Middle) C/O BAUDAX BIO, INC., 490 LAPP ROAD	3. Date of Earliest Transaction (Month/Day/Year) 06/15/2022	_X_ Officer (give title below) _X_ Other (specify below) Corporate Controller/Secretary / PFO and PAO
(Street) MALVERN, PA 19355	4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person
(City) (State) (Zip)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/15/2022		A		15,467 (1)	A	$ 0	15,738	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Dilmore Jillian C/O BAUDAX BIO, INC. 490 LAPP ROAD MALVERN, PA 19355			Corporate Controller/Secretary	PFO and PAO

Signatures

/s/ Jillian Dilmore		06/17/2022
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Each Restricted Stock Unit ("RSU") is the economic equivalent of one share of Baudax Bio, Inc. (the "Company") common stock, and may be settled, at the Company's option, in cash, shares of common stock, or a combination thereof. The RSUs vest 50% on June 15, 2023 and 50% on June 15, 2024, in each case subject to continued service with the Company through the applicable vesting date. Upon vesting, if settled in cash, each RSU will entitle the grantee to a cash-payment equal to the "Fair Market Value" (as defined in the Company's 2019 Equity Incentive Plan) of one share of the Company's common stock on the applicable vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Exhibit 24.1

OWER OF AT

KNOW ALL BY THESE PRESENT
appoints Gerri Henwood of Baudax Bio, Inc. (the "
undersigned's true and lawful attorney-in-fact, with full

1) execute for and on behalf of the undersigned,
and/or director and/or beneficial owner of the
with Section 16(a) of the Securities Exchange
thereunder;

2) do and perform any and all acts for and on
necessary or desirable to complete and execut
execute any amendment or amendments the
United States Securities and Exchange Comm
authority; and

3) take any other action of any type whatsoever i
the opinion of such attorney-in-fact, may be of
required by, the undersigned, it being underst
attorney-in-fact on behalf of the undersigned p
in such form and shall contain such terms an
approve in such attorney-in-fact's discretion.

The undersigned hereby grants the att
perform any and every act and thing whatsoever requisi
any of the rights and powers herein granted, as fully to
or could do if personally present with full power of

confirming all that such attorney-in-fact or such attorn
do or cause to be done by virtue of this power of attorne

This power of attorney shall remain
undersigned in a signed writing delivered to the attorne

IN WITNESS WHEREOF, the und
executed as of this 01st day of April, 2022.

Jillian Dilmore
Co
Corporate Con